Source comparison
Effectiveness Comparison
Clinical efficacy data for PT-141 comes from well-controlled Phase III trials, while Melanotan II evidence relies primarily on small-scale studies and anecdotal reports[27]. The RECONNECT study (NCT02333071), a 24-week randomized controlled trial involving 1,2
This comparison does not assign a generated winner or score.
- Clinical efficacy data for PT-141 comes from well-controlled Phase III trials, while Melanotan II evidence relies primarily on small-scale studies and anecdotal reports[27]. The RECONNECT study (NCT02333071), a 24-week randomized controlled trial involving 1,247 premenopausal women with HSDD, demonstrated PT-141's therapeutic efficacy[28]. Participants receiving PT-141 1.75 mg subcutaneously showed a 25% increase in satisfying sexual events compared to baseline, versus 17% with placebo (p<0.001)[29]. The Female Sexual Function Index (FSFI) desire domain scores improved by 0.3 points with PT-141 versus 0.1 points with placebo[30].
- Additional PT-141 efficacy data from the Phase III program shows 35% of women achieved meaningful improvement in sexual desire, defined as ≥1.2-point increase in FSFI desire domain scores[31]. The peptide demonstrated consistent effects across different age groups, with women aged 18-39 showing 27% improvement in satisfying sexual events and those aged 40-49 showing 23% improvement[32]. Onset of action typically occurs within 45 minutes of subcutaneous injection, with peak effects at 1-3 hours and duration lasting 6-12 hours[33].
- Satisfying sexual events (% change)
- +25%
- +17%
- <0.001
- FSFI desire domain (mean change)
- +0.3
- +0.1
- Sexual distress (% reduction)
- -28%
- -20%
- 0.003
- Treatment response (% patients)
- 35%
- 24%
- Melanotan II effectiveness data comes primarily from uncontrolled studies and user reports rather than rigorous clinical trials[34]. A small study of 10 men with erectile dysfunction showed 8 participants experienced improved erections within 6 hours of 0.025 mg/kg subcutaneous injection[35]. However, this study lacked placebo control and proper statistical analysis[36]. Regarding tanning effects, Melanotan II produces visible skin darkening in 85-90% of users within 3-5 days at doses of 0.25-1.0 mg daily[37]. The pigmentation effect persists for 4-6 weeks after discontinuation, gradually fading as melanocytes return to baseline activity[38].
- Sexual effects of Melanotan II appear less predictable than PT-141, with approximately 60-70% of male users reporting enhanced libido or erectile function[39]. However, these reports lack standardized outcome measures and proper control groups[40]. The peptide's appetite suppression effects are more consistent, with 80-90% of users experiencing 15-30% reduction in caloric intake within 24-48 hours of administration[41]. For patients seeking evidence-based sexual enhancement therapy, our sexual wellness treatment guide provides comprehensive information about FDA-approved options.